Odin Pharmaceuticals

Executive Summary

Odin Pharmaceuticals is a pre-revenue biotechnology company headquartered in Cambridge, Massachusetts, focused on developing novel therapeutics for neurological disorders and rare diseases. Founded in 2019, the company operates in early-stage discovery and preclinical development, targeting areas of high unmet medical need. While specific pipeline details are not publicly disclosed, Odin's strategic emphasis on CNS and orphan indications suggests a commitment to advancing therapies where current treatment options are limited. The company's early-stage profile implies significant upside potential if its candidates demonstrate favorable safety and efficacy profiles, but also carries substantial development risk typical of preclinical biotech ventures. Odin's ability to attract funding and secure partnerships will be critical for advancing its programs toward clinical trials.

Upcoming Catalysts (preview)

• Q4 2026Preclinical Proof-of-Concept Data for Lead Program30% success
• Q2 2027IND Filing for First Candidate25% success
• Q3 2026Series A Financing Announcement50% success